Drug Trial Radar · NCT03815695
A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients
Last checked: Nov 19, 2026Latest source record: Apr 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
130
Actual
Start
Dec 11, 2018
Primary completion
Dec 17, 2021
Study completion Dec 17, 2021
Sponsor
- Lead sponsor
- Forma Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.
- First posted
- Jan 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
FT-4202 is an oral small-molecule agonist of pyruvate kinase red blood cell isozyme (PKR) being developed for the treatment of hemolytic anemias. This initial study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of FT-4202 in the context of Phase 1 studies in healthy volunteers and sickle cell disease patients. The effects of food on the absorption of FT-4202 will also be evaluated in healthy volunteers.
Conditions
- Healthy Volunteers
- Sickle Cell Disease
Interventions
FT-4202/PlaceboDrug
Participants will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, frequency, and severity of adverse events (AEs) per CTCAE v5.0 of a single ascending dose and multiple ascending doses of FT-4202 in adult healthy volunteers and SCD patients.Time frame: Up to 3 weeks of monitoring
- Maximum observed plasma concentration (Cmax)Time frame: Up to 3 weeks of testing
- Time to maximum observed plasma concentration (Tmax)Time frame: Up to 3 weeks of testing
- Area under the plasma concentration-time curve from time zero until the 24-hour time point (AUC0-24)Time frame: Up to 3 weeks of testing
- Area under the plasma concentration-time curve from time zero until the last quantifiable time point (AUC0-last)Time frame: Up to 3 weeks of testing
- Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf)Time frame: Up to 3 weeks of testing
- Terminal elimination half-life (t1/2)Time frame: Up to 3 weeks of testing
- Apparent clearance (CL/F)Time frame: Up to 3 weeks of testing
- Apparent volume of distribution (Vd/F)Time frame: Up to 3 weeks of testing
- Terminal disposition rate constant (Lz)Time frame: Up to 3 weeks of testing
- Renal clearance (ClR)Time frame: Up to 3 weeks of testing
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Woodland International Research Group (SCD subjects only)
Little Rock, Arkansas
Collaborative Neuroscience Research, LLC (SCD subjects only)
Long Beach, California
Pacific Research Partners (SCD subjects only)
Oakland, California
UCSF Benioff Children's Hospital Oakland (SCD subjects only)
Oakland, California
Advanced Pharma CR, LLC (SCD subjects only)
Miami, Florida
Children's Healthcare of Atlanta (SCD subjects only)
Atlanta, Georgia
Augusta University Medical Center (SCD subjects only)
Augusta, Georgia
University of Illinois at Chicago (SCD subjects only)
Chicago, Illinois
University of Maryland, Greenebaum Comprehensive Cancer Center (SCD subjects only)
Baltimore, Maryland
Columbia University Medical Center (SCD subjects only)
New York, New York
Levine Cancer Institute (SCD subjects only)
Charlotte, North Carolina
Duke University Medical Center (SCD subjects only)
Durham, North Carolina
University of Cincinnati Medical Center (SCD subjects only)
Cincinnati, Ohio
Medpace Clinical Pharmacology Unit (Healthy Volunteers only)
Cincinnati, Ohio
Cincinnati Children's Hospital Medical Center (SCD subjects only)
Cincinnati, Ohio
Lynn Institute of Tulsa (SCD subjects only)
Tulsa, Oklahoma
St. Jude Children's Research Hospital (SCD subjects only)
Memphis, Tennessee
The University of Texas Health Science Center at Houston (SCD subjects only)
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.